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Abstract
Background The present study aimed to characterise the prevalence and prognostic impact of normocytic anaemia in patients
undergoing curative treatment for colorectal cancer.
Methods All individuals invited to the first round of bowel cancer screening, diagnosed with colorectal cancer and treated with curative
intent fromApril 2009 toMarch 2011 in a single health boardwere included. ThemodifiedGlasgow prognostic score (mGPS)was used
to quantify preoperative systemic inflammation. Patients were grouped as havingmicrocytic anaemia (Hb < 130mg/Lmales, < 120mg/
L females and MCV <80 fL), normocytic anaemia (Hb < 130 mg/L males, < 120 mg/L females and MCV 80–100 fL), or neither.
Results Of 395,097 patients invited to screening during the study period, 872 were diagnosed with colorectal cancer. Seven hundred
seventy-seven patients had FBC measured at diagnosis, of which 78 (10%) had microcytic anaemia, and 180 (23%) normocytic
anaemia. Onmultivariate binary logistic regression, microcytic anaemiawas associatedwith Tstage (OR 1.92, 95%CI 1.26–2.91, p =
0.002) and mGPS (OR 1.57, 95% CI 1.10–2.24, p = 0.013), while normocytic anaemia was associated with colonic tumours (OR=
2.51, 95% CI 1.10–4.01, p = 0.025), T stage (OR 1.38, 95% CI 1.05–1.81, p = 0.022), and mGPS (OR 1.52, 95% CI 1.12–2.05, p =
0.007). On univariate Cox regression, there was no significant association between microcytic anaemia and cancer specific survival
(CSS) (p = 0.969). Normocytic anaemia was significantly associated with poorer CSS (HR 1.55, 95% CI 1.13–2.12, p = 0.007).
Conclusions Normocytic anaemia was associated with systemic inflammation and poorer CSS. Inflammation may drive both
anaemia and disease recurrence in these patients, and targeting this process may improve both.
Keywords Anaemia . Colorectal cancer . Systemic inflammation
Introduction
Up to 40% of patients undergoing elective surgery for colo-
rectal cancer are found to be anaemic, and up to 30% require
allogeneic transfusion of packed red cells (PRCs) during the
perioperative period [1]. Such blood transfusions are associ-
ated with directly related adverse events such as major and
minor incompatibility reactions, and have also been reported
to be associated with higher rates of postoperative infective
complication, and with higher rates of disease recurrence [2].
It is thought that the negative impacts of short-term infective
and longer term oncologic outcomes in patients undergoing
surgery for colorectal cancer may relate to relative suppression
of the host adaptive immune system; however, the exact
mechanisms remain unclear [3].
The most common reason for perioperative blood transfu-
sion, even in the postoperative period, is preoperative anaemia
[4]. Anaemia itself has been reported to be an adverse prog-
nostic factor in patients with colorectal cancer. Traditionally,
in colorectal cancer, anaemia has been thought to relate to iron
deficiency due to frank and/or occult gastrointestinal blood
loss with resultant microcytosis [5]. Therefore, there have
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been great efforts toward iron replacement therapy in the pre-
operative period. However, a recent observational study re-
ported that normocytic anaemia was almost twice as prevalent
as microcytic anaemia in 356 patients with colorectal cancer
undergoing surgery with curative intent [6]. Furthermore,
normocytic anaemia was associated with poorer prognosis in
this cohort, whereas microcytic anaemia was not. The authors
reported a significant association between this normocytic
anaemia and preoperative systemic inflammation,
characterised by the modified Glasgow prognostic score,
which is itself a negative prognostic marker in this patient
group [7]. Furthermore, iron replacement therapy would be
unlikely to be useful in this group of patients. However, such
data was not collected and the cohort size did not allow for
meaningful subgroup analysis.
Therefore, the purpose of the present observational study
was to investigate the relationship between anaemia subtypes,
systemic inflammation and outcomes in patients treated with
curative intent for colorectal cancer.
Patients and methods
Patients
Details of all individuals who were invited to the first round
of the Scottish Bowel Screening Programme from April
2009 to the end of March 2011 in NHS Greater Glasgow
and Clyde (NHS GG&C) were extracted from the prospec-
tively maintained NHS GG&C Bowel Screening IT System
(original date of extraction January 2012, updated April
2014). They included all individuals in NHS GGG&C aged
between 50 and 74 years who were registered with a general
practitioner. Methodological data on the screening algorithm
used and processing of samples in the SBoSP have been
described previously [8]. At the time of study period, this
was a combined gFOBt/FIT screening programme. Data
were extracted on individuals invited for screening, includ-
ing the combined gFOBt/FIT result and the uptake and re-
sult of colonoscopy.
All individuals invited for screening in this first round were
cross-referenced with the prospectively maintained West of
Scotland Colorectal Cancer Managed Clinical Network
(MCN) dataset, and also linked to the Scottish Cancer
Registry (SMR06). This allowed the identification of any pa-
tient with a diagnosis of colorectal cancer. As screening invi-
tations were biennial, patients with cancer detected more than
720 days after invitation to screening were excluded. Patients
with colorectal cancer were then categorised as having screen-
detected disease (SD) or non-screen-detected disease (NSD).
This cohort of first-round screening patients has been de-
scribed previously [9].
Methods
Patient records were then interrogated on a case-by-case basis
to identify further clinicopathological variables for analysis.
Preoperative staging techniques, postoperative surveillance
strategies and timingwere uniform across the centres compris-
ing the health board. Tumours were staged according to the
conventional tumour node metastasis (TNM) classification
(fifth edition). Polyp cancers that were managed endoscopi-
cally and did not undergo formal resection were assumed to be
node negative and classified as TNM stage I. Additional high-
risk tumour features, such as poor differentiation, the presence
of venous invasion, peritoneal involvement and margin in-
volvement, were identified from pathology reports.
Patients were classified as having anaemia based on WHO
guidelines for males; haemoglobin (Hb) < 130 mg/L and fe-
males; Hb < 120 mg/L [10]. Furthermore, anaemic patients
were classified as having microyctic anaemia with mean cor-
puscular volume (MCV) < 80 f/L, normocytic anaemia with
MCV 80–100 f/L or macrocytic anaemia withMCV> 100 f/L.
Both the modified Glasgow prognostic score (mGPS) and
the neutrophil to lymphocyte ratio (NLR) were used as markers
of the preoperative SIR and were obtained from preoperative
blood results takenmost immediately and notmore than 6weeks
before surgery. Serum concentrations of C-reactive protein
(CRP) (mg/L) were measured using an autoanalyser
(Architect; Abbot Diagnostics, Maidenhead, UK) with a lower
detectable limit of 0.2 mg/L as was serum albumin (normal
range 35–50 g/L). The preoperative mGPS is CRP ≤ 10 mg/
L = 0 (CRP > 10 mg/L and albumin ≥ 35 g/L = 1;
CRP >10 mg/L and albumin < 35 g/L = 2), associated with can-
cer specific survival in multiple solid tumours, was calculated in
patients for whom serum CRP and albumin concentrations were
available [11]. A previously validated threshold of an NLR ≥ 5
was used as evidence of a significantly elevated SIR [12].
Statistical analysis
Associations between categorical variables were examined
using the χ2 test. For ordered variables with multiple catego-
ries, the χ2 test for a linear trend was used. Fisher’s exact test
was used for assessing associations where the expected indi-
vidual cell counts were less than five. Variables found to be
significantly associated with microcytic and normocytic anae-
mia with a p value < 0.05 at univariate level were entered into
a multivariate binary logistic regression using a backward
conditional model. Survival analysis comparing type of anae-
mia was performed using Kaplan-Meier curves and the log-
rank test. Univariate and multivariate survival analysis was
then performed using Cox’s proportional hazards model.
Variables associated with disease specific or overall survival
at a significance level of p < 0.1 on univariate analysis were
included in multivariate modelling using backward
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conditional regression where a two-sided p value < 0.05 was
considered statistically significant. Disease-specific survival
was defined as time from date of surgery to date of cancer
specific death. Overall survival was defined as time from date
of surgery to date of death from any cause. Those who died in
the immediate postoperative period were excluded from sur-
vival analysis. Statistical analysis was performed using SPSS
software (SPSS version 24, Chicago, Illinois, USA).
Permission for the study was granted by the Caldicott
Guardian of the screening dataset and by the West of
Scotland Colorectal Cancer MCN Management Group. Data
were stored and analysed in an anonymized manner.
Results
Patients
Of 395,097 patients invited to screening during the study pe-
riod (Supplementary data 1), within 2 years of their screening
invite, 872 patients (0.2%) were diagnosed with colorectal
cancer. Of these, 6 (0.7%) patients are with macrocytic anae-
mia and 89 (10%) are without FBC were excluded. Seven
hundred seventy-seven (89%) patients had a full blood count
(FBC) measured at diagnosis and were included in the study
of which 78 (10%) had microcytic anaemia and 180 (23%)
normocytic anaemia.
The majority of the patients were male (458, 59%), over
65 years old (519, 67%), with non-screen-detected (451,
58%), node negative (515, 66%) disease of the colon (525,
68%). The median follow-up period of those alive at the time
of censoring was 63 months (range 32–83). During the
follow-up period, there were 210 (27%) deaths of which 116
(15%) were due to colorectal cancer.
Association between microcytic anaemia, normocytic
anaemia and clinicopathological variables
When those patients without anaemia, with microcytic anae-
mia, and normocytic anaemia were compared (Table 1), there
were significant differences in the proportions of patients with
screen-detected cancer (48% vs. 28% vs. 31%, p < 0.001),
aged over 65 (63% vs. 73% vs. 76% p = 0.004), ASA 3–4
(29% vs. 54% vs. 41%, p < 0.001), undergoing nCRT (15%
vs. 0% vs. 14%, p = 0.001), rectal cancer (38% vs. 14% vs.
24%, p < 0.001), T stage 3–4 (54% vs. 90% vs. 82%,
p < 0.001), N stage 1–2 (30% vs. 41% vs. 41%, p < 0.001),
NLR ≥ 5 (12% vs. 24% vs 21%, p = 0.002), and mGPS 1–2
(18% vs. 59% vs. 46%, p < 0.001).
At multivariate binary logistic regression (Table 2), only T
stage (OR 1.92, 95% CI 1.26–2.91, p = 0.002), and mGPS
(OR 1.57, 95% CI 1.10–2.24) remained independently asso-
ciated with microcytic anaemia.
At multivariate binary logistic regression (Table 2), nCRT
(OR 4.69, 95%CI 1.87–11.75, p = 0.001), colonic cancer (p =
0.025), T stage (OR 1.38, 95% CI 1.05–1.81, p = 0.022), and
mGPS (OR 1.52, 95% CI 1.12–2.05, p = 0.007) remained in-
dependently associated with normocytic anaemia.
Relationship between T stage, systemic inflammation
and haematological parameters
When the 535 patients with a recordedmGPSwere stratified by
T stage and mGPS, there were significant associations with Hb,
MCV and the prevalence of both microcytic and normocytic
anaemia (Table 3). Of the 535, 166 (31%) had both a T stage of
0–2 andmGPS of 0, while 143 (27%) had both a Tstage of 3–4
and mGPS of 1–2. When these two extreme groupings were
compared, they were found to respectively have the highest and
lowest median Hb (138 vs. 117 g/L, p < 0.001) and MCV (91
vs. 85 f/L, p < 0.001), and the lowest and highest prevalence of
microcytic anaemia (2% vs. 24%, p < 0.001) and normocytic
anaemia (13% vs. 41%, p < 0.001).
Prognostic impact of microcytic, normocytic anaemia
and systemic inflammation
At Kaplan-Meier analysis (Fig. 1), those patients with
normocytic anaemia had a significantly poorer 5-year can-
cer-specific survival (78%), than those with microcytic anae-
mia (86%) or no anaemia (87%) (p = 0.022). In contrast, both
those patients with normocytic anaemia (71%) and microcytic
anaemia (70%) had a similarly poor overall survival when
compared to patients without anaemia (82%) (p = 0.001).
When only patients with colonic cancers were included
(Fig. 2), the results were similar, in that those patients with
normocytic anaemia had a significantly poorer 5-year cancer-
specific survival (82%), than those with microcytic anaemia
(90%) or no anaemia (92%) (p = 0.031). Again, both those
patients with normocytic anaemia (75%) and microcytic anae-
mia (77%) had a similarly poor overall survival when com-
pared to patients without anaemia (86%) (p = 0.048).
When patients were grouped by anaemia (either microcytic
or normocytic) and inflammation (mGPS 0 or 1–2)
(Supplementary data 2), those patients who were inflamed
alone had a significantly poorer 5-year cancer-specific surviv-
al (64%) than those with both anaemia and inflammation
(78%), those with anaemia alone (85%) and those who were
neither anaemic nor inflamed (92%) (p < 0.001). In contrast,
both those patients who were anaemic and inflamed (63%)
and those who were inflamed alone (61%) had a similar but
significantly poorer 5-year overall survival when compared to
patients who were anaemic alone (81%), and those with nei-
ther anaemia or inflammation (87%) (p < 0.001).
At multivariate Cox regression (Table 4), screen detection
(HR 0.53, 95% CI 0.29–0.99, p = 0.046), TNM stage (HR
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Table 1 Clinicopathological
characteristics amongst patients
with screen and non-screen-
detected colorectal cancer treated
with curative intent grouped by
anaemia at diagnosis
Anaemia None, n (%) Microcytic, n (%) Normocytic, n (%) p
n 519 78 180 –
Demographic
Presentation
Non-screen-detected 271 (52) 56 (72) 124 (69) < 0.001
Screen detected 248 (48) 22 (28) 56 (31)
Sex
Male 306 (59) 50 (64) 102 (57) 0.537
Female 213 (41) 28 (36) 78 (43)
Age
< 64 193 (37) 21 (27) 44 (24) 0.004
64–70 178 (34) 22 (28) 61 (34)
> 70 148 (29) 35 (45) 75 (42)
ASA (n = 660)
1 72 (16) 8 (12) 10 (7) < 0.001
2 242 (55) 23 (34) 80 (52)
3 122 (28) 35 (51) 55 (36)
4 3 (1) 2 (3) 8 (5)
Neoadjuvant treatment
Yes 77 (15) 0 (0) 26 (14) 0.001
No 442 (85) 78 (100) 154 (86)
Pathological
Tumour site
Colon 323 (62) 67 (86) 135 (76) < 0.001
Rectum 196 (38) 11 (14) 43 (24)
T stage
0/1 143 (28) 3 (4) 11 (6) < 0.001
2 92 (18) 5 (6) 22 (12)
3 220 (42) 42 (54) 94 (52)
4 64 (12) 28 (36) 53 (30)
N stage
0 364 (70) 46 (59) 105 (59) < 0.001
1 111 (22) 17 (22) 44 (25)
2 43 (8) 15 (19) 29 (16)
Differentiation
Well/Mod 479 (93) 70 (90) 182 (90) 0.458
Poor 37 (7) 8 (10) 17 (10)
Venous invasion
Present 241 (49) 46 (61) 99 (57) 0.067
Absent 247 (51) 30 (39) 74 (43)
Systemic inflammation
NLR
≥ 5 65 (12) 19 (24) 38 (21) 0.002
< 5 454 (88) 59 (76) 142 (79)
mGPS (n = 529)
0 276 (82) 25 (41) 72 (54) < 0.001
1 31 (9) 11 (18) 10 (8)
2 29 (9) 25 (41) 50 (38)
ASA American Society of Anesthesiology, SD screen detected, NSD non-screen-detected, NLR neutrophil lym-
phocyte ratio, mGPS modified Glagow prognostic score, MCV mean corpuscular volume
£Males = Hb < 130 g/L, females < 120 g/L
$Anaemia and MCV< 80 fL
*Anaemia and MCV 80–100 fL
&Anaemia and MCV> 100 fL
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2.89, 95% CI 2.06–4.05, p < 0.001), poor differentiation (HR
2.18, 95% CI 1.20–3.94, p = 0.010), and mGPS (HR 1.37,
95% CI 1.02–1.83, p = 0.035) remained independently asso-
ciated with cancer-specific survival.
At multivariate Cox regression (Table 4), screen detection
(HR 0.51, 95%CI 0.31–0.83, p = 0.008), ASA (HR 1.39, 95%
CI 1.03–1.87, p = 0.033), TNM stage (HR 1.92, 95%CI 1.49–
2.46, p < 0.001), and poor differentiation (HR 2.57, 95% CI
1.57–4.20, p < 0.001) remained independently associatedwith
overall survival.
Discussion
The results of the present study report a significant association
between T stage, systemic inflammation and anaemia, both mi-
crocytic and normocytic, in patients undergoing curative treat-
ment for colorectal cancer. Although normocytic anaemia ap-
pears to be associated with poorer oncologic outcome at multi-
variate analysis, TNM stage and systemic inflammation were of
greater importance. It may be that the systemic inflammatory
process is a key driver of anaemia in this group of patients, which
could be of great important in their perioperative management.
Vayrynen and colleagues recently reported the prognostic sig-
nificance of microcytic anaemia and its association with the host
systemic inflammatory response in a small cohort of patients with
stages I–III colorectal cancer [6]. The findings of the present study
are in keeping with this work, and indeed provide external vali-
dation. The finding that this normocytic anaemia of inflammation
is both twice as prevalent as microcytic anaemia, traditionally
associated with colorectal cancers due to frank and/or occult gas-
trointestinal blood loss, and is associated with poorer prognosis is
an important one. However, unlike the previous study, the present
study also reports an independent association between systemic
inflammation and microcytic anaemia. Therefore, it may be that
Table 2 Multivariate binary
logistic regression of factors
associated with microcytic and
normocytic anaemia
Variable Microcytic$ anaemia£ Normocytic* anaemia£
Multivariate OR (95% CI) p Multivariate OR (95% CI) p
Screen detected – 0.262 – 0.385
Age – 0.458 1.31 (0.96–1.79) 0.089
ASA – 0.832 1.42 (0.99–2.04) 0.056
nCRT – 0.997 4.69 (1.87–11.75) 0.001
Rectal cancer – 0.346 0.43 (0.20–0.90) 0.025
T stage 1.92 (1.26–2.91) 0.002 1.38 (1.05–1.81) 0.022
N stage – 0.896 – 0.722
NLR ≥5 – 0.788 – 0.684
mGPS 1.57 (1.10–2.24) 0.013 1.52 (1.12–2.05) 0.007
ASA American Society of Anesthesiology, SD screen detected, NSD non-screen-detected, NLR neutrophil lym-
phocyte ratio, mGPS modified Glagow prognostic score, MCV mean corpuscular volume
£Males = Hb < 130 g/L, females < 120 g/L
$Anaemia and MCV< 80 fL
*Anaemia and MCV 80–100 fL
Table 3 Relationship between T stage, systemic inflammation and
haematological parameters in (n = 535)
Number of patients, n
T stage
All 0–2 3–4
mGPS
All 535 179 356
0 379 166 213
1–2 154 13 143
Haemoglobin, median, range (mg/L)
T stage p
All 0–2 3–4
mGPS
All 132 (60–194) 138 (82–184) 128 (60–194) < 0.001
0 134 (73–194) 138 (82–184) 131 (73–194) < 0.001
1–2 118 (60–181) 139 (90–162) 117 (60–181) 0.066
p < 0.001 0.933 <0.001 < 0.001
MCV, median, range (fL)
T stage p
All 0–2 3–4
mGPS
All 90 (60–110) 91 (66–108) 88 (60–110) <0.001
0 86 (61–103) 91 (73–108) 90 (61–107) 0.016
1–2 85 (60–105) 90 (72–103) 85 (60–105) 0.247
p < 0.001 0.683 < 0.001 < 0.001
Microcytic$ anaemia£, n (%)
T stage p
All 0–2 3–4
mGPS
All 61 (11) 6 (3) 55 (15) < 0.001
0 25 (7) 4 (2) 21 (10) 0.004
1–2 36 (23) 2 (15) 34 (24) 0.492
p <0.001 0.013 < 0.001 < 0.001
Normocytic* anaemia£, n (%)
T stage p
All 0–2 3–4
mGPS
All 132 (25) 23 (13) 109 (31) < 0.001
0 72 (19) 21 (13) 51 (24) 0.006
1–2 60 (39) 2 (15) 58 (41) 0.074
p < 0.001 0.677 0.001 < 0.001
mGPSmodified Glagow prognostic score,MCVmean corpuscular volume
£Males = Hb < 130 g/L, females < 120 g/L
$Anaemia and MCV< 80 fL
*Anaemia and MCV 80–100 fL
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the host innate inflammatory response is a key mechanism under-
pinning both types of anaemia in this group of patients.
Due to the prevalence of preoperative anaemia in patients
with colorectal cancer, and its association with postoperative
morbidity, up to 30% of such patients receive a perioperative
blood transfusion [2]. Allogeneic transfusion of PRCs has been
reported to be itself associated with both increased risk of
postoperative infective complications [13] and disease recur-
rence in patients with colorectal cancer [2]. Therefore, there
has been great interest in preoperative iron replacement therapy
in anaemic patients in attempt to reduce blood transfusion rates.
Several studies, including a recent RCT in colorectal surgery,
have reported that parenteral iron replacement is associated
with a reduced perioperative blood transfusion requirement
Fig. 2 Kaplan-Meier survival charts of a cancer specific (log-rank p = 0.031) and b overall survival (p = 0.048) grouped by anaemia at diagnosis in
patients undergoing treatment with curative intent for colonic cancer
Fig. 1 Kaplan-Meier survival charts of a cancer specific (log-rank p = 0.015) and b overall survival (p = 0.002) grouped by anaemia at diagnosis in
patients undergoing treatment with curative intent for colorectal cancer
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when compared to placebo [14, 15]. A further RCT in colorec-
tal surgery compared parenteral and enteral iron replacement
finding that intravenous iron supplementation was associated
with higher preoperative haemoglobin but finding no difference
in perioperative blood transfusion rates [16]. However, no study
of iron replacement to date has taken into account the effect of
systemic inflammation, in the diagnosis, stratification or out-
come assessment of this group of patients [17].
It is clear that systemic inflammation alters both iron homeo-
stasis and erythropoiesis through the IL-6-dependent peptide hor-
mone hepcidin. Hepcidin acts on enterocytes and the reticuloen-
dothelial system to reduce iron absorption from the gastrointesti-
nal tract, and to promote sequestration of iron, therefore reducing
iron available for erythropoiesis but not whole body iron stores
[18]. This can lead to a state of functional iron deficiency such as
that seen in patientswith colorectal cancerwho have a normocytic
anaemia of inflammation [19]. These physiological effects may
render iron replacement, especially via the oral route, either less
effect or ineffective in colorectal cancer patients with a systemic
inflammatory response. Of additional concern is the possibility
that inappropriate iron replacement in patients with underlying
malignancy may potentiate disease recurrence [20, 21].
Even more difficult in the preoperative assessment of these
patients is that fact that the presence of systemic inflammation
leads to significant perturbment of the common serum mea-
sures of iron status, including ferritin, transferrin, and transferrin
saturation, upon which clinical decisions regarding iron re-
placement therapy and/or blood transfusion are often made
[22]. Not only is it unclear, therefore, whether patients who
are anaemic with a co-existing systemic inflammatory response
will benefit from iron replacement therapy, but it can also be
difficult with current laboratory testing to determine which pa-
tients are in fact truly iron deficient.
The main limitations of the present study include the lack of
data regardingmeasures of iron status at the timeof diagnosis, and
data regarding subsequent treatment with iron replacement or
blood transfusion. Furthermore, not all patients had an mGPS re-
corded at the time of diagnosis, reducing the sample size for
Table 4 Univariate and
multivariate cox regression of
factors associated with cancer
specific and overall survival
amongst patients with screen, and
non-screen-detected stage I-III
colorectal cancer treated with cu-
rative intent
Variable
Univariate HR (95% CI) p Multivariate HR (95% CI) p
CSS
Screen detected 0.35 (0.23–0.55) < 0.001 0.53 (0.29–0.99) 0.046
Sex 1.03 (0.71–1.51) 0.867 – –
Age 0.91 (0.72–1.14) 0.391 – –
ASA 1.44 (1.09–1.92) 0.011 – 0.795
nCRT 1.37 (0.83–2.28) 0.218 – –
Rectal cancer 0.81 (0.53–1.23) 0.327 – –
TNM stage 3.34 (2.63–4.23) < 0.001 2.89 (2.06–4.05) < 0.001
Differentiation 3.49 (2.19–5.57) < 0.001 2.18 (1.20–3.94) 0.010
Venous invasion 2.78 (1.80–4.29) < 0.001 1.92 (0.99–3.70) 0.053
NLR ≥ 5 2.17 (1.41–3.34) < 0.001 – 0.519
mGPS 1.95 (1.53–2.48) < 0.001 1.37 (1.02–1.83) 0.035
Microcytic anaemia 0.99 (0.52–1.89) 0.969 – –
Normocytic anaemia 1.76 (1.18–2.62) 0.005 – 0.158
OS
Screen detected 0.42 (0.30–0.57) < 0.001 0.51 (0.31–0.83) 0.008
Sex 0.93 (0.69–1.26) 0.644 – –
Age 1.12 (0.94–1.33) 0.217 – –
ASA 1.69 (1.35–2.11) < 0.001 1.39 (1.03–1.87) 0.033
nCRT 1.31 (0.88–1.97) 0.186 – –
Rectal cancer 0.95 (0.69–1.31) 0.756 – –
TNM stage 2.03 (1.72–2.41) < 0.001 1.92 (1.49–2.46) < 0.001
Differentiation 2.62 (1.76–3.89) < 0.001 2.57 (1.57–4.20) < 0.001
Venous invasion 1.85 (1.35–2.53) < 0.001 – 0.238
NLR ≥5 2.24 (1.61–3.13) < 0.001 – 0.412
mGPS 1.82 (1.50–2.21) < 0.001 1.24 (0.97–1.58) 0.090
Microcytic anaemia 1.41 (0.91–2.18) 0.126 – –
Normocytic anaemia 1.55 (1.13–2.12) 0.007 1.52 (0.99–2.34) 0.057
ASA American Society of Anesthesiology, CSS cancer-specific survival, HR hazard ratio, SD screen detected,
NSD non-screen-detected, nCRT neoadjuvant chemoradiotherapy, NLR neutrophil lymphocyte ratio,mGPSmod-
ified Glagow prognostic score, MCV mean corpuscular volume, OS overall survival
£Males = Hb < 130 g/L, females < 120 g/L
$Anaemia and MCV< 80 fL
*Anaemia and MCV 80–100 fL
Int J Colorectal Dis
subsequent examination of the relationship between mGPS, T
stage and haematological parameters. The retrospective nature of
thestudycoupledwith the fact that thecohortwasderivedfromthe
prevalence roundof a screeningprogramme limited the additional
data which could be captured. Colonic and rectal cancers were
analysed together as the relatively smallnumberof survival events
prevented meaningful subgroup analysis. Despite this, the data is
in keepingwith, and validates similar previous work.
In conclusion, the present study reports that systemic in-
flammation as measured by mGPS and T stage are indepen-
dently associated with both normocytic and microcytic anae-
mia in patients with colorectal cancer treated with curative
intent. Furthermore, normocytic anaemia, but not microcytic
anaemia, was associated with poorer cancer specific survival,
although the presence of systemic inflammation appears to of
greater importance in this group of patients. Further studies
should first seek to examine the impact of these factors on
measures of iron status in this population. This would hope-
fully allow detailed work to study the impact of perioperative
blood transfusion and iron replacement in anaemic colorectal
cancer patients with systemic inflammation. Subsequent trials
of preoperative iron replacement should report the potential
confounding effect of the systemic inflammatory response and
stratify patients accordingly.
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